SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who wrote (955)1/29/2000 2:39:00 PM
From: Pseudo Biologist  Read Replies (1) of 4474
 
Thanks; to clarify, I see three major classes of constructs:

(1) those leading to proteins that "float" free inside the cytoplasm.

(2) those with a myristoylation sequence, so that the resulting protein remains associated with the membrane from the inside, but has no surface marker. This is what I called "surface-less" before.

(3) the newer construct that replaces the myristoylation sequence by full TM+extracellular domains. This is the cell surface-tagged described in the 1999 Amara paper.

2 and 3 are obviously very different from 1, with 2 or 3 more suitable for dimerizer-triggered apoptosis via a Fas-like system.

My comment referred to the differences between 2 and 3, which do not appear to me that fundamental. Still, I can see a quantitative advantage for 3 ("clustering") plus a qualitative one (possibility to use immunoselection of transduced cells).

Hope this is clear now.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News